This document discusses the use of ranibizumab (Lucentis) to treat choroidal neovascularization (CNV) secondary to pathologic myopia. It summarizes several case studies on the effects of ranibizumab treatment for myopic CNV. A series of 23 patients with myopic CNV who received ranibizumab treatment showed a mean visual acuity gain of 9.53 letters after 12 months. Most patients (77%) gained over 1 line of vision. No patients experienced moderate vision loss. The results suggest ranibizumab may effectively prevent vision loss and improve vision for CNV caused by pathologic myopia with very few needed treatments and no observed safety risks.